Pardes Biosciences, Inc.
News
Pardes Biosciences Announces Closing of Tender Offer
Globe Newswire CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully ...\n more…
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
Business Wire As previously announced, on July 16, 2023, MediPacific Sub, Inc. (Purchaser) and MediPacific, Inc. (Parent), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the Merger Agreement) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes) whereby Purchaser agreed...\n more…
Critical Comparison: Pardes Biosciences (NASDAQ:PRDS) vs. NuCana (NASDAQ:NCNA)
Zolmax NuCana (NASDAQ:NCNA Get Free Report) and Pardes Biosciences (NASDAQ:PRDS Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, ...\n more…
Analyzing Pardes Biosciences (NASDAQ:PRDS) & NuCana (NASDAQ:NCNA)
Ticker Report Pardes Biosciences (NASDAQ:PRDS Get Free Report) and NuCana (NASDAQ:NCNA Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership...\n more…
Pardes Biosciences (NASDAQ:PRDS) Lowered to "Market Perform" at JMP Securities
Ticker Report Pardes Biosciences (NASDAQ:PRDS Get Free Report) was downgraded by analysts at JMP Securities from an outperform rating to a market perform rating in a note issued to investors on Tuesday, Marketbeat reports. Several other research analysts have also recently ...\n more…